Skip to main content
Premium Trial:

Request an Annual Quote

Precipio AML HemeScreen

Precipio launched a new HemeScreen panel for acute myeloid leukemia that returns results in four hours and determines the genetics of the disease. The test is intended to be used at oncology physician office laboratories and uses a single-sample plate to test blood samples for a variety of genes related to AML. It tests for FLT3, which can indicate how aggressive the disease is; CEBPA, which can provide prognostic information; NPM1, which can serve as a monitoring tool for minimal residual disease; IDH1, which is associated with decreased complete remission and IDH2 which is often associated with IDH1; and KIT, which reveals a poor prognosis and need for more aggressive treatment.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.